Progression-free survival in the ICON8 trial
نویسندگان
چکیده
منابع مشابه
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.
The standard phase II trial design has changed dramatically over the past decade. Randomized phase II studies have essentially become the standard phase II design in oncology for a variety of reasons. The use of these designs is motivated by concerns about the use of historical data to determine if a new agent or regimen shows promise of activity. However, randomized phase II designs come with ...
متن کاملEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
IMPORTANCE Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation. OBJECTIVE To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma. DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label, phase 2 clinical trial comparing selumetinib v...
متن کاملBayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival.
Delivering radiation to eradicate a solid tumor while minimizing damage to nearby critical organs remains a challenge. For esophageal cancer, radiation therapy may damage the heart or lungs, and several qualitatively different, possibly recurrent toxicities associated with chemoradiation or surgery may occur, each at two or more possible grades. In this article, we describe a Bayesian group seq...
متن کاملAssessing the value of progression-free survival (AVALPROFS).
187 Background: Controversy exists about progression free survival (PFS) as an endpoint in novel cancer therapy trials. PFS is attractive for practical and methodological reasons but is not always a surrogate for overall survival. It is debatable whether or not PFS has discernable clinical benefit for patients (pts), the main treatment (tmt) goal. Also overlooked are pt perceptions. Few trials ...
متن کاملProgression-free survival remains debatable endpoint in cancer trials.
I n recent years the U.S. Food and Drug Administration has approved cancer therapies on the basis of improved progression-free survival (PFS), including several drugs for the treatment of metastatic kidney cancer. Clinicians who treat kidney cancer patients are convinced that the agency made the right move, and some even contend that overall survival (OS) is no longer a useful endpoint in this ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 2020
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(20)31175-2